At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
ABT-333 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-333 After Discontinuation of ABT-333 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-333 Clinical Studies
In Brief
A Phase 2 clinical trial evaluating Blood sample collection only and ABT-333 for HCV Infection. Completed, enrolled 35 participants across 7 sites in 2 countries.
Detailed Summary
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHCV Infection
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2008
Enrollment StartAug 2008
Primary CompletionMay 2010
TodayJul 2026
First PostedAug 1, 2008
Enrollment StartAug 1, 2008
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.9 years ago
Interventions
Blood sample collection onlyprocedure
Approximately monthly collection of blood samples.
ABT-333drug
Previous treatment in prior ABT-333 studies.